Some studies of Sarepta Therapeutics' muscular dystrophy drug, Elevidys, have been halted by European regulators after a ...

Pfizer still has another obesity pill in development, PF-07976016, which is currently in a Phase IIa trial. The gold standard ...

Edgewise Therapeutics shares tumbled more than 20% Wednesday after the developmental drug company issued the results of its ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

Fixed and flexible doses of tavapadon significantly improved motor function compared with placebo in patients with ...

Vaxcyte is awaiting data from another vaccine candidate for invasive pneumococcal disease (IPD) before advancing to Phase III.

Veeva Systems VEEV recently introduced SiteVault, a Clinical Trial Management System (CTMS) designed for research sites. It integrates with SiteVault eISF and SiteVault eConsent, enabling sites to ...

Viking Therapeutics (NASDAQ: VKTX) is operating in one of the highest-growth pharma areas around. Viking doesn't sell weight loss drugs yet, but it could be on the way. The biotech is studying ...

LH's growth opportunities in important specialty testing areas are robust. Expanding through strategic acquisitions is an added plus.

The imminent trials against Meta and Google offer opportunities to chip away at Big Tech’s power, a rare shared goal of the Biden and Trump administrations.